Current Urology Reports

, Volume 14, Issue 4, pp 269–278

Daily Dosing of PDE5 Inhibitors: Where Does it Fit in?

Men's Health (J Mulhall, Section Editor)

DOI: 10.1007/s11934-013-0342-9

Cite this article as:
Lee, K.C.J. & Brock, G.B. Curr Urol Rep (2013) 14: 269. doi:10.1007/s11934-013-0342-9

Abstract

To provide a critical contemporary review of daily PDE5-inhibitor (PDE5-I) use in urological and nonurological conditions. PDE5-Is can be taken up to once a day. However, at present only tadalafil is approved for use in both erectile dysfunction (ED) and benign prostate hyperplasia (BPH) with lower urinary tract symptoms (LUTS). Evolving research in penile rehabilitation, Peyronie’s disease, male infertility, pulmonary arterial hypertension, muscular dystrophy and Raynaud’s phenomenon shows these therapeutic areas may also benefit from PDE5i therapy. This review examines the role of chronic PDE5 inhibition in ED, BPH-LUTS and other therapeutic targets which may shape our clinical practice in the years to come.

Keywords

PDE5 inhibitors Daily use LUTS Benign prostate hyperplasia Erectile dysfunction 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of UrologyNational University HospitalSingaporeSingapore
  2. 2.Division of Urology, St Joseph’s Health CareUniversity of Western OntarioLondonCanada

Personalised recommendations